Join us for a summary of the latest developments in MBC research presented at the annual San Antonio Breast Cancer Symposium (SABCS), 2024. Dr. Debu Tripathy, breast oncologist at The University of Texas MD Anderson Cancer Center, will break down the data, explain what it means, and answer questions.
Key Takeaways from this Webinar:
- Ember-3 Study: Compared standard treatment to a newer selective oral selective estrogen receptor degrader (SERD), imlunestrant, with abemaciclib for second line therapy in HR+/HER2-neg MBC. The results showed imlunestrant is superior to endocrine therapy alone in patients who have an ESR1 mutation.
- AFT-38 Patina Study: Showed encouraging results when combining cyclin-dependent kinase (CDK) 4/6 inhibition with HER2-targeted therapy for first line therapy of HER2+ MBC
- PHILA Study: Studied combining HER2 antibody plus HER kinase inhibitor for HER2+ MBC and found a benefit to adding pyrotinib to trastuzumab and docetaxel therapy.
ReDiscover trial: A newer mutant kinase-specific PI3Kα inhibitor, RLY-2608, showed promising results in patients with HR+/HER2- MBC who have PIK3CA-mutation present in the blood or tumor. - Improving nausea control: When compared to prochlorperazine, olanzapine showed increased nausea control in patients receiving chemotherapy leading to a significant improvement in quality of life.
